0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Do Cyclooxygenase-2 Inhibitors Provide Benefits Similar to Those of Traditional Nonsteroidal Anti-Inflammatory Drugs, with Less Gastrointestinal Toxicity?

Mark Feldman, MD; and Alexander T. McMahon, MBA
[+] Article and Author Information

From University of Texas Southwestern Medical Center, Dallas, Texas; and Salix Pharmaceuticals, Inc., Palo Alto, California.


Note added in proof: The equal efficacy of celecoxib and naproxen in rheumatoid arthritis, with fewer endoscopic ulcers in the celecoxib groups, was reported in a recent paper (Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal efects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999; 282:1921-8).

Disclaimer: Dr. Feldman performed clinical studies of rofecoxib for Merck and Co., Inc., before the drug received FDA approval. He currently has no consulting or financial arrangements with any company that manufactures NSAIDs or COX-1-COX-2 inhibitors. Mr. McMahon and Salix Pharmaceuticals, Inc., have no current financial interest in the use of NSAIDs or COX-1-COX-2 inhibitors for the treatment of arthritis or other conditions and are not now involved in the manufacture of any related drugs or products.

Acknowledgments: The authors thank Drs. Byron Cryer, Ping Hsu, Lorin Johnson, and Salahuddin Kazi for their useful comments and Vicky Robertson for helping prepare the manuscript.

Grant Support: By the Veterans' Administration (Merit Award to Dr. Feldman).

Requests for Reprints: Mark Feldman, MD, Medical Service (111), Dallas Veterans Affairs Medical Center, 4500 South Lancaster Road, Dallas, TX 75216; e-mail, mark.feldman@med.va.gov. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints@mail.acponline.org.

Current Author Addresses: Dr. Feldman: Medical Service (111), Dallas Veterans Affairs Medical Center, 4500 South Lancaster Road, Dallas, TX 75216.

Mr. McMahon: Oncology Therapeutics Network, 345 Oyster Point Boulevard, Suite 405, South San Francisco, CA 94080.


Ann Intern Med. 2000;132(2):134-143. doi:10.7326/0003-4819-132-2-200001180-00008
Text Size: A A A

Two forms of cyclooxygenase, cyclooxygenase-1 (COX-1) and cyclooxygenase 2 (COX-2), act as rate-limiting enzymes in prostaglandin and thromboxane synthesis. Discovery of these compounds led to the development of drugs that selectively or specifically inhibit the COX-2 isoform. Although the COX-1 isoform is expressed at fairly constant levels in cells, including the gastrointestinal mucosa and platelets, expression of COX-2 varies greatly. In many cells, low expression of COX-2 can be upregulated by various stimuli, including inflammatory cytokines, bacterial toxins, and growth factors; this suggests that COX-2 plays a role in inflammation, infection, and cellular proliferation.

It was thought that newly developed drugs designed to block COX-2 but not COX-1 would have anti-inflammatory properties and would avoid inhibiting the synthesis of gastrointestinal prostaglandins (thereby avoiding ulcers) and platelet thromboxane (thereby avoiding bleeding). Gastrointestinal ulcers and bleeding are side effects of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) that block COX-1 and COX-2. Meloxicam and nimesulide, selective COX-2 inhibitors available outside the United States, are as effective as traditional NSAIDs but have similar gastrointestinal side effects. Celecoxib (Celebrex, G.D. Searle and Co., Chicago, Illinois) and rofecoxib (Vioxx, Merck and Co., Inc., West Point, Pennsylvania), selective COX-2 inhibitors approved in the United States in the past year, are also as effective as traditional NSAIDs. However, celecoxib and rofecoxib have no antiplatelet activity and lead to fewer endoscopically detected gastric and duodenal ulcers than traditional NSAIDs, such as ibuprofen or naproxen.

Preliminary analyses of data pooled from several trials suggest that celecoxib and rofecoxib are associated with fewer clinically symptomatic ulcers and ulcer complications than traditional NSAIDs are. Postmarketing surveillance should help clarify the actual risk for serious ulcer complications with these new COX-2 inhibitors and reveal other potential nongastrointestinal toxic reactions that can result from their use.

Figures

Grahic Jump Location
Figure 1.
Chemical structures of celecoxib (Celebrex, G.D. Searle and Co., Chicago, Illinois) and rofecoxib (Vioxx, Merck and Co., Inc., West Point, Pennsylvania).

Celecoxib has a sulfonamide side group, and rofecoxib has a methylsulfonyl side group. Celecoxib is contraindicated in patients who are allergic to sulfonamides.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Reactions catalyzed by cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2).2PGG 2 2PGH 2 222222222α2α2222

These cyclooxygenases convert arachidonic acid (20:4), a fatty acid constituent of membrane phospholipids, to prostaglandin G ( ) (cyclooxygenase reaction) and then to prostaglandin H ( ) (peroxidase reaction). Prostaglandin H is then converted by cells to prostaglandins or thromboxane A . Cyclooxygenase-1 is also known as PGH synthase-1, and cyclooxygenase-2 is also known as PGH synthase-2. PGD = prostaglandin D ; PGE = prostaglandin E ; PGF = prostaglandin F ; PGI = prostaglandin I ; PGJ = prostaglandin J .

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)